Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (375)	5/20/1999 1:48:00 AM
From: Vector1	Read Replies (3) \| Respond to of 3158

Peter, I think INCY should buy/merge with Pharmacopia and ABSC. The combination of 1. world class genetic databases (INCY) 2. robust chip technology (INCY) 3. world class combichem and database technology (PCOP) 4. 120 person sales force (PCOP) and 5. most powerful high throughput screening system (ABSC) would create an incredibly powerful company that could offer big pharma truly one stop shopping. The cost to INCY assuming a 40% premium would be under $500m. Am I loosing it? V1